Tumor doses of 4,500 rads in 5 weeks are adequate for control of subclinical aggregates of cancer cells from adenocarcinoma of the breast. This dose is well tolerated with negligible, if any, sequelae. Disease in moderate-sized axillary or supraclavicular lymph nodes can be permanently controlled, depending upon the size, by 6,000 to 7,000 rads in 6 to 7 weeks.